Defence Therapeutics Inc. (FRA:DTC)

Market Cap	28.38M
Revenue (ttm)	n/a
Net Income (ttm)	-2.21M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6,334
Open	0.4430
Previous Close	0.4780
Day's Range	0.4430 - 0.4430
52-Week Range	0.3170 - 1.1700
Beta	n/a
RSI	45.88
Earnings Date	Nov 19, 2025

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DTC

Financial Performance

Financial numbers in CAD